1.07
+0.04(+3.88%)
Currency In USD
| Previous Close | 1.03 |
| Open | 1.05 |
| Day High | 1.11 |
| Day Low | 1.03 |
| 52-Week High | 1.5 |
| 52-Week Low | 0.52 |
| Volume | 2.23M |
| Average Volume | 5.73M |
| Market Cap | 312.47M |
| PE | -5.35 |
| EPS | -0.2 |
| Moving Average 50 Days | 1 |
| Moving Average 200 Days | 0.83 |
| Change | 0.04 |
If you invested $1000 in Ocugen, Inc. (OCGN) 10 years ago, it would be worth $2.8 as of July 31, 2025 at a share price of $1.07. Whereas If you bought $1000 worth of Ocugen, Inc. (OCGN) shares 5 years ago, it would be worth $2,077.67 as of July 31, 2025 at a share price of $1.07.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Ocugen, Inc. Announces New Appointments to Retina Scientific Advisory Board & Executive Leadership Team
GlobeNewswire Inc.
Jul 21, 2025 11:30 AM GMT
MALVERN, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced updates to its Retina Scientific Advisory Board (SAB) a
Ocugen, Inc. Announces First Patient Dosed in Phase 2/3 GARDian3 Pivotal Confirmatory Trial for OCU410ST—Novel Modifier Gene Therapy Candidate for Stargardt Disease
GlobeNewswire Inc.
Jul 18, 2025 11:02 AM GMT
MALVERN, Pa., July 18, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the first patient has been dosed in its Phase 2/3
Ocugen to Host Conference Call on Friday, August 1 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2025 Financial Results
GlobeNewswire Inc.
Jul 17, 2025 10:30 AM GMT
MALVERN, Pa., July 17, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a conference call and live webcast to